RHHBY Stock Recent News
RHHBY LATEST HEADLINES
Cullen Roche says the Fed is "thinking in a proactive sense" after announcing a 50BPS rate cut. He points to Fed Chair Jerome Powell's transparency to help "reduce the risk of a hard landing.
Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health market with acquisition of Veri.
Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). OCREVUS ZUNOVO is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC) injection approved for both these forms of multiple sclerosis, giving people living with MS more treatment options.
The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.
RHHBY's Accu-Chek Smartguide will provide several predictive features aimed at enhancing patient safety. However, the device may face tough competition from existing CGM devices.
Roche, a big pharmaceutical company, recently shared details from an early-stage trial with its oral anti-obesity candidate. Roche's oral anti-obesity candidate outperformed a similar candidate from Viking Therapeutics in terms of efficacy.
The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple sclerosis.
RHHBY's data on experimental obesity drug, CT-996, disappoints investors on higher incidence of adverse events.
A study of a closely-watched experimental Roche obesity pill has been tied to side effects, including nausea and vomiting, in a small study. The results raise questions for investors evaluating whether the novel medicine can compete with the next generation of weight loss drugs in a market expected to top $130 billion annually by the end of the decade.
The storied European pharmaceutical is forging ahead in its efforts to develop a weight loss treatment. Recent news from the lab about the medication is not encouraging, however.